Tuberculosis, Human Immunodeficiency Virus, and the Association With Transient Hyperglycemia in Periurban South Africa.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
14 08 2020
Historique:
received: 31 05 2019
accepted: 16 09 2019
pubmed: 27 9 2019
medline: 28 4 2021
entrez: 27 9 2019
Statut: ppublish

Résumé

Diabetes mellitus (DM) increases tuberculosis (TB) risk. We assessed the prevalence of hyperglycemia (DM and impaired glucose regulation [IGR]) in persons with TB and the association between hyperglycemia and TB at enrollment and 3 months after TB treatment in the context of human immunodeficiency virus (HIV) infection. Adults presenting at a Cape Town TB clinic were enrolled. TB cases were defined by South African guidelines, while non-TB participants were those who presented with respiratory symptoms, negative TB tests, and resolution of symptoms 3 months later without TB treatment. HIV status was ascertained through medical records or HIV testing. All participants were screened for DM using glycated hemoglobin and fasting plasma glucose at TB treatment and after 3 months. The association between TB and DM was assessed. Overall DM prevalence was 11.9% (95% confidence interval [CI], 9.1%-15.4%) at enrollment and 9.3% (95% CI, 6.4%-13%) at follow-up; IGR prevalence was 46.9% (95% CI, 42.2%-51.8%) and 21.5% (95% CI, 16.9%-26.3%) at enrollment and follow-up. TB/DM association was significant at enrollment (odds ratio [OR], 2.41 [95% CI, 1.3-4.3]) and follow-up (OR, 3.3 [95% CI, 1.5-7.3]), whereas TB/IGR association was only positive at enrollment (OR, 2.3 [95% CI, 1.6-3.3]). The TB/DM association was significant at enrollment in both new and preexisting DM, but only persisted at follow-up in preexisting DM in patients with HIV-1 infection. Our study demonstrated high prevalence of transient hyperglycemia and a significant TB/DM and TB/IGR association at enrollment in newly diagnosed DM, but persistent hyperglycemia and TB/DM association in patients with HIV-1 infection and preexisting DM, despite TB therapy.

Sections du résumé

BACKGROUND
Diabetes mellitus (DM) increases tuberculosis (TB) risk. We assessed the prevalence of hyperglycemia (DM and impaired glucose regulation [IGR]) in persons with TB and the association between hyperglycemia and TB at enrollment and 3 months after TB treatment in the context of human immunodeficiency virus (HIV) infection.
METHODS
Adults presenting at a Cape Town TB clinic were enrolled. TB cases were defined by South African guidelines, while non-TB participants were those who presented with respiratory symptoms, negative TB tests, and resolution of symptoms 3 months later without TB treatment. HIV status was ascertained through medical records or HIV testing. All participants were screened for DM using glycated hemoglobin and fasting plasma glucose at TB treatment and after 3 months. The association between TB and DM was assessed.
RESULTS
Overall DM prevalence was 11.9% (95% confidence interval [CI], 9.1%-15.4%) at enrollment and 9.3% (95% CI, 6.4%-13%) at follow-up; IGR prevalence was 46.9% (95% CI, 42.2%-51.8%) and 21.5% (95% CI, 16.9%-26.3%) at enrollment and follow-up. TB/DM association was significant at enrollment (odds ratio [OR], 2.41 [95% CI, 1.3-4.3]) and follow-up (OR, 3.3 [95% CI, 1.5-7.3]), whereas TB/IGR association was only positive at enrollment (OR, 2.3 [95% CI, 1.6-3.3]). The TB/DM association was significant at enrollment in both new and preexisting DM, but only persisted at follow-up in preexisting DM in patients with HIV-1 infection.
CONCLUSIONS
Our study demonstrated high prevalence of transient hyperglycemia and a significant TB/DM and TB/IGR association at enrollment in newly diagnosed DM, but persistent hyperglycemia and TB/DM association in patients with HIV-1 infection and preexisting DM, despite TB therapy.

Identifiants

pubmed: 31557282
pii: 5574636
doi: 10.1093/cid/ciz928
pmc: PMC7428387
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1080-1088

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI115940
Pays : United States
Organisme : Wellcome Trust
ID : FC0010218
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 104873
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 084323
Pays : United Kingdom
Organisme : Cancer Research UK
ID : FC001010218
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States
Organisme : Wellcome Trust
ID : 203135
Pays : United Kingdom

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Int J Tuberc Lung Dis. 2010 Dec;14(12):1513-7
pubmed: 21180207
Int J Tuberc Lung Dis. 2015 Sep;19(9):1098-101
pubmed: 26260832
PLoS One. 2011;6(8):e24215
pubmed: 21912626
Trop Med Int Health. 2013 Jul;18(7):822-9
pubmed: 23648145
Indian J Psychol Med. 2013 Apr;35(2):121-6
pubmed: 24049221
Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):459-68
pubmed: 21663839
BMC Infect Dis. 2013 Mar 05;13:122
pubmed: 23497232
J Infect. 2007 Oct;55(4):340-6
pubmed: 17631968
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Trop Med Int Health. 2010 Nov;15(11):1300-14
pubmed: 20958887
Lancet. 2009 May 23;373(9677):1798-807
pubmed: 19465235
Public Health Action. 2013 Nov 4;3(Suppl 1):S10-7
pubmed: 26393062
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
BMC Med. 2011 Jul 01;9:81
pubmed: 21722362
Antivir Ther. 2010;15(4):571-7
pubmed: 20587850
Eur Respir J. 2017 Jul 20;50(1):
pubmed: 28729474
Clin Infect Dis. 2015 Feb 1;60(3):453-62
pubmed: 25313249
Diabetes Care. 2013 Jan;36 Suppl 1:S4-10
pubmed: 23264424
J Infect Dis. 2016 Apr 1;213(7):1163-72
pubmed: 26609005
PLoS One. 2012;7(9):e43336
pubmed: 22962583
Trop Med Int Health. 2017 Mar;22(3):261-268
pubmed: 27935650
Tubercle. 1990 Jun;71(2):135-8
pubmed: 2219464
Curr Diab Rep. 2018 Aug 9;18(9):71
pubmed: 30090969
Bull World Health Organ. 2018 Nov 1;96(11):738-749
pubmed: 30455529
PLoS One. 2017 Oct 23;12(10):e0186697
pubmed: 29059214
PLoS Med. 2008 Jul 15;5(7):e152
pubmed: 18630984
Int J Infect Dis. 2018 Apr;69:11-19
pubmed: 29253707
Diabetologia. 2015 Jul;58(7):1409-21
pubmed: 25994072
Diabetes Care. 2012 Apr;35(4):797-802
pubmed: 22323413

Auteurs

Mmamapudi Kubjane (M)

Division of Public Health Medicine, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa.

Natacha Berkowitz (N)

Division of Public Health Medicine, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa.
Wellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, and Department of Medicine, University of Cape Town, Observatory, South Africa.

Rene Goliath (R)

Wellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, and Department of Medicine, University of Cape Town, Observatory, South Africa.

Naomi S Levitt (NS)

Division of Diabetes and Endocrinology, Department of Medicine, Groote Schuur Hospital, Cape Town, South Africa and Chronic Disease Initiative for Africa.

Robert J Wilkinson (RJ)

Wellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, and Department of Medicine, University of Cape Town, Observatory, South Africa.
The Francis Crick Institute, London, United Kingdom.
Department of Infectious Diseases, Imperial College London, United Kingdom.

Tolu Oni (T)

Division of Public Health Medicine, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa.
Wellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, and Department of Medicine, University of Cape Town, Observatory, South Africa.
Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH